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Available online 7 November 2015Cannabidiol (CBD) is a non-psychoactive constituent of Cannabis sativawith potential to treat neurodegenerative
diseases. Its neuroprotection has beenmainly associatedwith anti-inﬂammatory and antioxidant events; howev-
er, other mechanisms might be involved. We investigated the involvement of neuritogenesis, NGF receptors
(trkA), NGF, and neuronal proteins in the mechanism of neuroprotection of CBD against MPP+ toxicity in PC12
cells. CBD increased cell viability, differentiation, and the expression of axonal (GAP-43) and synaptic
(synaptophysin and synapsin I) proteins. Its neuritogenic effect was not dependent or additive to NGF, but it
was inhibited by K252a (trkA inhibitor). CBD did not increase the expression of NGF, but protected against its de-
crease induced by MPP+, probably by an indirect mechanism. We also evaluated the neuritogenesis in SH-SY5Y
cells, which do not express trkA receptors. CBD did not induce neuritogenesis in this cellular model, which sup-
ports the involvement of trkA receptors. This is the ﬁrst study to report the involvement of neuronal proteins and
trkA in the neuroprotection of CBD. Our ﬁndings suggest that CBD has a neurorestorative potential independent
of NGF that might contribute to its neuroprotection against MPP+, a neurotoxin relevant to Parkinson's disease.







Cannabidiol (CBD) is a non-psychoactive compound of Cannabis
sativa with anti-inﬂammatory and antioxidant properties and conse-
quently, a potential for neuroprotection (Zuardi et al., 2006;
Fernandez-Ruiz et al., 2013). Several studies have suggested the poten-
tial of CBD in the treatment of neurodegenerative diseases (ND) such as
Parkinson's disease (PD) (Chagas et al., 2014), Alzheimer's disease (AD)
(Fernandes-Ruiz et al., 2005) and Huntington's disease (HD) (Sagredo
et al., 2007). Despite that, the precisemolecularmechanisms underlying
the therapeutic potential of CBD remain unclear. Many targets of CBD
such as receptors, ion channels, enzymes and transporters have beenrived neurotrophic factor; CBD,
ssociated protein; GDNF, glial-
isease; MPP+, 1-methyl-4-
rmeability transition; MTT,
nerve growth factor; PD,
rs.
nalyses, Toxicology and Food
Preto, University of São Paulo,identiﬁed (Fernandez-Ruiz et al., 2013); however, the role of
neuritogenesis in the neuroprotection of CBD has not been clariﬁed yet.
Neurite loss is an early event in neurodegenerative diseases and the
regeneration of the network of neurites constitutes a strategy for the
treatment of such disorders. Neurotrophic factors play a critical role in
neuronal regeneration, but their clinical use is limited by their inability
to cross the blood brain barrier (Gottlieb et al., 2010). It is noteworthy
that, CBD is not psychoactive, but it can readily cross the blood brain
barrier and exert its beneﬁcial effects on the brain (Deiana et al.,
2012). The trophic signaling of nerve growth factor (NGF) has been as-
sociated with the prevention of neuronal apoptosis mediated by activa-
tion of the anti-apoptotic protein Bcl2. The lack of stimulation by NGF
and the resulting inactivation of Bcl2 trigger the intrinsic pathway
(mitochondrial) of apoptosis through mitochondrial permeability tran-
sition (MPT), release of cytochrome c and activation of the caspase cas-
cade (Wolozin and Behl, 2000).
Loss and dysfunction of trophic factors seem to be involved in the
pathogenesis of AD and PD (Connor and Dragunow, 1998; Siegel and
Chauhan, 2000). Decrease of neurotrophic factors such as BDNF and
NGF has been reported in the brain and cerebrospinal ﬂuid of PD pa-
tients (Mogi et al., 1999; Nagatsu et al., 2000). Additionally, a study
showed signiﬁcant reduction of serum levels of NGF in parkinsonian
rats and in patients with PD. Interestingly, NGF levels in early stages of
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vanced stages (Grades III–IV) (Lorigados Pedre et al., 2002).
Based on these premises, the present study investigated the
neurorestorative potential of CBD and the pathways that mediate it by
using PC12 cells treated with the neurotoxin MPP+, a metabolite of
MPTP (1-methyl-4-phenyl-1,2,5,6tetrahydropyridine), known to in-
duce Parkinsonism in vivo. The involvement of the NGF-pathway
was evaluated by using a speciﬁc inhibitor of trk receptors and two
cell lines (PC12 and SH-SY5Y) with distinct phenotypes for these recep-
tors. The role of NGF in the protective mechanism of CBD was also
investigated.2. Materials and methods
2.1. Chemicals
Only high purity reagents were used (analytical grade minimum).
Reagents were obtained from Sigma-Aldrich®, unless speciﬁed differ-
ently. Cell culture media and reagents were purchased from Invitrogen
(Carlsbad, CA). Reagents for Western blot were purchased from Bio-
Rad®. Type I water (ultra-pure) obtained in the puriﬁcation system by
reverse osmosis (Rios DI-3), followed by puriﬁcation in a Milli-Q Gradi-
ent system (Millipore, Bedford, USA) was used in the preparation of so-
lutions. CBD was obtained from THC-Pharm, Frankfurt, Germany. CBD
solutions were prepared in DMSO, and therefore controls were treated
with the same volume of DMSO.2.2. Cellular cultures
PC12 and SH-SY5Y cells were obtained from the American Type Cul-
ture Collection, ATCC (Rockville, MD).
PC12 cellswere grown inDMEMhigh glucosewith 10% horse serum,
5% fetal bovine serum and 1% PNS (5 mg/ml penicillin, 10 mg/ml neo-
mycin and 5 mg/ml streptomycin, GIBCO®). PC12 cells were cultured
in 75 cm2 tissue-culture ﬂasks at 37 °C under a humidiﬁed atmospheric
condition of 5% CO2 and 95% air. Medium was replaced every 2 days.
Conﬂuent cultures were washed with pre-warmed phosphate buffered
saline (PBS), detached with trypsin/EDTA solution (GIBCO®),
inactivated with growth medium, centrifuged, and subcultured (1:2;
every 7–9 days). Third-passage cells with 80% conﬂuence were used in
the experiments.
SH-SY5Y cells were grown in F12 nutrientmixture (F12HAM; Sigma
Cell Culture, St. Louis, MO) supplemented with 15% fetal bovine serum
(GIBCO) and 1% PNS. Cells were cultured in 75 cm2 tissue-culture ﬂasks
at 37 °C under a humidiﬁed atmospheric condition of 5% CO2 and 95%
air. Mediumwas replaced every day. Conﬂuent cultures were detached
with trypsin/EDTA solution (GIBCO®), inactivated with growth medi-
um, centrifuged, and subcultured (1:2; every 2–3 days). Third-passage
cells with 80% conﬂuence were used in the experiments.2.3. MPP+/PC12 model
The rat pheochromocytoma cell line PC12 is awidely used cellmodel
to study neuronal differentiation. The toxicity was induced with 1 mM
MPP+ (IC50) for cell-viability-related assays (MTT and caspase-3) or
100 μM MPP+ (sub-lethal concentration) for neurite-related assays.
These concentrations were based on our previous ﬁndings showing
that the impairment of neurite outgrowth is an early event that pre-
cedes cell death and occurs at sub-lethal concentrations of MPP+ (dos
Santos et al., 2014). Cells were plated in 12-well (neurites assay) or
96-well (cell viability) plates at the appropriate density for each assay
and incubated for 24 h prior to the following additions: 1 mM/100 μM
MPP+; CBD (1, 5, 10, 25 and 50 μM); and 1 mM/100 μMMPP+ + CBD
(1, 5 and 10 μM).2.4. Cell viability —MTT assay
The colorimetric assay MTT is the most widely used indicator of cell
viability. It evaluates the cellular mitochondrial function based on the
enzymatic reduction of the tetrazolium salt by mitochondrial dehydro-
genases of viable cells (Mosmann, 1983). A previously described proce-
dure (Hansen et al., 1989) with minor modiﬁcations was used. Treated
cells (2.0× 104 cells/well) were incubated in 96-well plates for 24 h. The
mediumwas removed and 20 μl ofMTT (5mg/ml in phosphate buffered
saline) was added to each well (ﬁnal concentration 0.5 mg/ml). Then
the plate was incubated for 3 h at 37 °C. A negative control
(cells + MTT solution) and a positive control (cells + Triton X-
100 + 0.2% MTT solution) were assayed. After the incubation period,
the supernatant was removed and 200 μl DMSO was added to promote
cell lysis. The plate wasmixed (37 °C, 5min) and absorbancewas deter-
mined at 570 nm, in a microplate reader (Multiskan FC, Thermo
Scientiﬁc).2.5. Caspase-3 activity
An aliquot of 1 ml of cell suspension (107 cells/ml) was incubated
with 1 mMMPP+ (positive control) or 1 mM MPP+ plus 1 μM CBD in
24-well plates (at 37 °C, for 24 h). Controls were incubated without ad-
ditions. After that, themediumwas removed and cells were assayed for
caspase-3 activity by using the Colorimetric Caspase 3 Assay Kit (Sigma,
MO, USA) according to the manufacturer's instructions. The activity of
caspase-3 was assessed by monitoring the absorbance at 405 nm.2.6. Neurite outgrowth: quantitative assay in PC12 cells
PC-12 cells were incubated in 24-well plates (1 × 105 cells/well) for
24 h for adhesion. Then, the medium was replaced by Ham's F-12K
(Kaighn's) Medium supplemented with 1% horse serum and 1% antibi-
otic mixture (penicillin/streptomycin/neomycin, PSN GIBCO®). Cells
were then incubated (37 °C, 72 h) with one of the following additions:
1 μM CBD, NGF (“nerve growth factor from Vipera lebetina venom”,
100 ng/ml), 100 μM MPP+ or 100 μM MPP+ + 1 μM CBD. Untreated
cells were used as controls. The neurite outgrowth was assessed by
inverted phase contrast microscopy (Carl Zeiss Axio Observer A1
invertedmicroscope, 400×magniﬁcation). Phase-contrast photomicro-
graphs of 4 ﬁelds per well were taken after 72 h-incubation. The per-
centage of cells with neurites was determined in digitalized images by
using the Image J open source software (Rasband, 1997-2014). Only
those cells with at least one neurite with a length equal to or greater
than the diameter of the cell body were considered differentiated (Das
et al., 2004).2.7. Neurite outgrowth: quantitative assay in SH-SY5Y neuroblastoma cells
Cells were incubated in 24-well plates (3 × 104 cells/well) in F12
HAM supplementedwith 15% fetal bovine serum (FBS) and 1% antibiot-
ic mixture (penicillin/streptomycin/neomycin, PSN GIBCO®) for 24 h
for adhesion. After this period, the medium was replaced (F12 HAM
supplemented with 1% FBS, 1% PSN and retinoic acid 10 μM) and cells
were incubated for 7 days, during which the medium was renewed
every 2 days. Then, cells were treated with 1 μM CBD and incubated at
37 °C for 72 h. Untreated cells were used as controls. The neurite out-
growth was assessed by inverted phase contrast microscopy (Carl
Zeiss Axio Observer A1 inverted microscope, 400× magniﬁcation). The
percentage of cells with neurites was determined in digitalized images
by using the Image J open source software (Rasband, 1997-2014).
Only those cells with at least one neuritewith a length equal to or great-
er than the diameter of the cell body were considered differentiated
(Das et al., 2004).
233N.A.G. Santos et al. / Toxicology in Vitro 30 (2015) 231–2402.8. Trk receptors inhibition assay
K-252a (Sigma-Aldrich®, St. Louis,MO, USA) is a speciﬁc inhibitor of
trk (tyrosine kinase) receptors and thus, selectively blocks the effect
of nerve growth factor (NGF) and agonists of trkA in PC12 cells
(Tapley et al., 1992). PC-12 cells were incubated in 24-well plates
(2 × 105 cells) for 24 h for adhesion. Then, the medium was replaced
by Ham's F-12K (Kaighn's) Medium supplemented with 1% horse
serum and 1% PSN antibiotic (penicillin/streptomycin/neomycin
GIBCO®). Cells were then incubated (37 °C, 168 h), with one of
the following additions: CBD (1 μM), NGF (100 ng/ml), K252a
(100 nM)+ CBD (1 μM) and K252a (100 nM) + NGF (100 ng/ml). Un-
treated cells were used as controls. The neurite outgrowthwas assessed
by inverted phase contrast microscopy (Carl Zeiss Axio Observer A1
invertedmicroscope, 400×magniﬁcation). Phase-contrast photomicro-
graphs of 4 ﬁelds per well were taken after 72 h, 96 h, 120 h, 144 h and
168 h of incubation. The percentage of cells with neurites was deter-
mined in digitalized images by using the Image J open source software
(Rasband, 1997-2014). Only those cells with at least one neurite with
a length equal to or greater than the diameter of the cell bodywere con-
sidered differentiated (Das et al., 2004).2.9. Determination of NGF levels
Cells (2.0 × 105 cells/well) were plated in 24-well plates and incu-
bated at 37 °C for 24 h prior to the following additions: 1 μM CBD,
NGF 100 ng/ml (positive control), 100 μM MPP+ or 100 μM
MPP+ + 1 μM CBD (untreated cells were used as controls). Then cells
were incubated at 37 °C for 72 h. After that, an aliquot of 100 μl of the
supernatantwas analyzed by using the Enzyme-Linked Immunosorbent
Assay kit RAB0381 (Sigma-Aldrich®, St. Louis, MO, USA) as recom-
mended by the manufacturer. The absorbance at 450 nm was deter-
mined in a microplate reader (Multiskan FC, Thermo Scientiﬁc).2.10. Western blot analysis — synaptophysin, synapsin and GAP-43
After additions and incubation (72 h, 37 °C), cells (2× 105 cells/well)
were rinsed with cold PBS and mixed with 200 μl Tris–Triton lysis
buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA,
Triton X-100 1%, 10% glycerol, 0.1% SDS, 0.5% deoxycholate, 1:200 prote-
ase inhibitor cocktail, and 1% phosphatase inhibitor). The lysis proce-
dure was performed with tubes placed on ice to reduce the activity of
proteases. The cells were then harvested and transferred to centrifuge
microtubes and incubated (300 rpm, 30 min, 4 °C). After centrifugation
(12,000 rpm for 20 min at 4 °C), the precipitates were discarded, and
cell lysates (supernatants) were stored in a freezer (−80 °C) until
assayed. A 10 μl aliquot of each cell lysatewas assayed for protein deter-
mination by the Bradford method described below.2.10.1. Determination of protein in cell lysate (Bradford)
The reactive color Protein Assay Dye Reagent Concentrate (Bio-Rad)
was used according to the protocol suggested by the manufacturer. The
lysateswere dilutedwithwater (1:5) and a calibration curve of BSA (40,
100, 200 and 400 mg/ml) was prepared. The color reagent was diluted
with water (1:5). The color reaction was performed in 96-well plates
by adding 10 μl of diluted sample or standard and 200 μl of diluted
dye reagent. The absorbance (595 nm) was determined in a microplate
reader after 5 minute-agitation. Due to the known interference of some
components of the lysis buffer in the reaction of Bradford, controls con-
taining 10 μl of diluted lysis buffer were carried out and the average ab-
sorbance of them was subtracted from the absorbance values of
samples. Concentrations of protein in samples were calculated based
on the calibration curve response and multiplied by the dilution factor
(×5).2.10.2. SDS-PAGE
Samples were diluted in equal volume of Laemli sample buffer (2×)
and heated for 10 min at 95 °C. Aliquots of 35 μl containing 10 μg total
protein were applied to 10% polyacrylamide gel (10 wells) and separat-
ed by electrophoresis (1 h, 160 V) in an electrophoresis tank containing
1 l of Tris/glycine buffer (Bio-Rad).
2.10.3. Transfer
Proteins were transferred to nitrocellulose membranes (1 h, 0.37 A)
in an electrophoresis tank (Bio-Rad) containing 1 l of Tris/glycine/SDS
buffer (Bio-Rad).
2.10.4. Immune reaction
Themembranes were blocked (30min, RT, 300 rpm)with 5% BSA in
Tween 20/TBS buffer (TTBS), and incubated (overnight, 4 °C, 300 rpm)
with primary antibody: anti-synaptophysin (1:400), or anti-GAP-43
(1:1250), or anti-synapsin I, (1:1000);washedwith TTBS and incubated
(1 h, RT, 300 rpm)with a secondary antibody conjugated to horseradish
peroxidase (anti-mouse or anti-rabbit IgG-HRP, 1:20,000). The mem-
braneswerewashedwith TTBS and TBS and treatedwith 3ml of chemi-
luminescence enhancer detection reagents (1:1). Bands were detected
by chemiluminescence and images were captured by using a ChemiDoc
system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Quantitation of
the digitalized images was performed based on the optical densitome-
try (OD) of the bands by using the open source software Image J
(Rasband, 1997-2014). Subsequently membranes were stripped
(2% SDS, 62.5 mM Tris pH 6.8 and 100 mM mercaptoethanol) and
reprobed for β-actin protein (loading control). Immunoreaction was
carried out by using a monoclonal anti-β-actin antibody (1:3000) and
anti- mouse IgG-HRP (1:20,000). The procedures for chemiluminescent
detection were repeated. After quantiﬁcation of β- actin bands, OD
values of synaptophysin, synapsin and GAP-43 were divided by the
OD values of β-actin for normalization of the results (L'Episcopo et al.,
2011). All antibodies were purchased from Sigma-Aldrich® (St Louis,
MO, USA) and the dilutions used were within the range recommended
by the manufacturer.
2.11. Statistical analysis
Data shown are the mean ± standard error of the mean (SEM) of
three independent experiments performed in triplicate (n= 9). Statis-
tical comparisons were performed using One-way ANOVAwith Tukey's
multiple comparisons test and the software GraphPad Prism version
6:00 for Windows (La Jolla California USA). p b 0.05 was used as the
level of signiﬁcance.
3. Results
3.1. Cell death induced by MPP+. Dose–response curve
The values of the absorbance obtained from theMTT assaywere nor-
malized (0–100% range) and the concentrations of MPP+ were trans-
formed into the corresponding logarithm. The IC50 was calculated
using the equation: Y = 100/(1 + 10 ^ (LogIC50− X) ∗ hillslope) and
it was 0.9836 to 1.025 mM (95% conﬁdence interval). Therefore, the
concentration used in the viability assays was 1 mM. The non-linear re-
gression curve is presented in Fig. 1.
3.2. CBD increased cell viability in MPP+-treated PC12 cells
When assayed alone, CBD (10 μM) did not alter the viability of PC12
cells (94.39 ± 2.97) as compared to control (99.6% ± 1.05%). MPP+
(1mM) signiﬁcantly reduced cell viability (41.10%±0.39) as compared
to control (99.6 ± 1.05%). CBD signiﬁcantly increased cell viability
(1 μM, 62.56 ± 1.481%; 5 μM, 52.93 ± 1.27%; and 10 μM, 51.18 ±
1.33%) as compared to MPP+ alone (41.10% ± 0.39). Controls were
Fig. 3. Effect of CBD on caspase-3 activation. Data are representative of three independent
experiments; each experiment was performed in triplicate. *Signiﬁcantly different from
control group, #Signiﬁcantly different from MPP+, (p b 0.05).
Fig. 1. Effect ofMPP+ on viability of PC12 cells. Dose–response curve. Cells were incubated
(24 h/37 °C)with different concentrations ofMPP+ (0 to 5mM). IC50=1mM. The trace is
representative of three independent experiments; each experiment was performed in
triplicate.
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on controls (Fig. 2).
3.3. CBD decreased the activity of caspase-3 in MPP+-treated PC12 cells
MPP+ signiﬁcantly increased the activity of caspase-3 (0.1354 ±
0.00163) as compared to controls (0.0301 ± 0.01443); whereas CBD
decreased the activity of caspase-3 (0.04485 ± 0.01764) as compared
to the MPP+ group (Fig. 3).
3.4. CBD alone induced cellular differentiation on PC12 cells
CBD alone (27.19 ± 0.047%) and NGF (17.38 ± 0.93%) induced dif-
ferentiation in PC12 cells as compared to controls (10.14 ± 0.65%)
(Fig. 4A). Phase-contrast photomicrographs of controls, NGF and CBD
are presented in Fig. 4B,C and D, respectively.
3.5. K252a reduced the cellular differentiation induced by CBDon PC12 cells
No signiﬁcant difference was observed between cells treated with
K252a alone (72 h, 6.29 ± 0.15; 96 h, 14.42 ± 0.21; 120 h, 13.77 ±Fig. 2. Effect of CBD onMPP+-induced cell death. Data are representative of three indepen-
dent experiments; each experiment was performed in triplicate. *Signiﬁcantly different
from control group (p b 0.05).1.27; 144 h, 12.82±0.12 and 168 h, 6.32± 0.95) and controls (untreat-
ed, non-NGF stimulated cells) during the whole period of incubation.
NGF (72 h, 14.08 ± 0.74; 96 h, 22.26 ± 1.37; 120 h, 23.77 ± 1.99;
144 h, 21.19 ± 1.92 and 168 h, 14.90 ± 1.12%) and CBD (72 h,
12.99 ± 0.82; 96 h, 22.69 ± 1.18; 120 h, 21.67 ± 0.59; 144 h,
21.10 ± 1.48 and 168 h, 14.21 ± 0.95%) signiﬁcantly increased the dif-
ferentiation as compared to controls (72 h, 6.21 ± 0.22; 96 h, 14.50 ±
0.12; 120 h, 13.22 ± 0.87; 144 h, 12.44 ± 1.11 and 168 h, 6.39 ±
0.26). The percentage of differentiated cells in the NGF + K252a group
was decreased (72 h, 7.30 ± 0.81; 96 h, 12.85 ± 0.77; 120 h, 12.97 ±
0.54; 144 h, 8.98 ± 0.86; and 168 h, 6.66 ± 0.94%) as compared to
NGF alone (72 h, 14.08 ± 0.74; 96 h, 22.26 ± 1.37; 120 h, 23.77 ±
1.99; 144 h, 21.19 ± 1.92 and 168 h, 14.90 ± 1.12%). Differently from
NGF effect, the inhibition of CBD effect by K252a was only signiﬁcant
after 120 h of incubation (72 h, 12.68 ± 0.72; 96 h, 20.61 ± 0.88;
120 h, 15.65 ± 1.27; 144 h, 10.37 ± 0.63 and 168 h, 8.57 ± 0.67%) as
compared to CBD alone (72 h, 12.99 ± 0.82; 96 h, 22.69 ± 1.18;
120 h, 21.67 ± 0.59; 144 h, 21.10 ± 1.48 and 168 h, 14.21 ± 0.95%)
(Fig. 5A–E).
3.6. CBD protected against the inhibition of cellular differentiation induced
by MPP+
CBD signiﬁcantly increased the cellular differentiation (4.90 ± 0.59)
in cells treated with MPP+ (1.02+ 0.60) as presented in Fig. 6A. Phase-
contrast photomicrographs of the MPP+ group and the MPP+ + CBD
group are presented in Fig. 6B and C, respectively.
3.7. The effect of CBD on neuritogenesis is not additive to the effect of NGF
NGF (9.8 ± 0.41%), CBD (12.39 ± 0.70%) and CBD + NGF (12.77 ±
0.34%) increased the percentage of differentiated cells in relation to con-
trol (2.69± 0.25%). No signiﬁcant difference was observed between the
effects of CBD alone and CBD + NGF (Fig. 7).
3.8. CBD did not increase the levels of NGF in PC12 cells
MPP+ decreased (0.0053 ± 0.00067) and CBD did not signiﬁcantly
affect (0.021 ± 0.0018) the levels of NGF as compared to control
Fig. 4. Effect of CBD on differentiation of PC12 cells. Cells were incubated for 72 hwith/without NGF 100 ng/ml or CBD 1 μM. Cells with at least one neurite with a length equal to or greater
than the cell body were counted and expressed as a percentage of total cells in the ﬁeld. (A) Bar graph representing the mean ± SEM of 3 different experiments performed in triplicate
(n = 9). *Signiﬁcantly different from controls, p b 0.05. (B–D) Phase-contrast photomicrographs of (B) Control (no-treatment), (C) NGF 100 ng/ml and (D) CBD 1 μM.
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(0.0150± 0.0018) as compared toMPP+ alone. NGFwas added as pos-
itive control and its absorbance was signiﬁcantly higher (0.034 ±
0.0025) than control (0.026 ± 0.0008) (Fig. 8).Fig. 5. Effect of CBD on the differentiation of PC12 cells treatedwith K252a (trk inhibitor). Cells w
and analyzed after (A) 72h, (B), 96 h, (C), 120 h, (D) 144h and (E) 168 h. Cellswith at least onen
percentage of total cells in the ﬁeld. The results are expressed as mean ± SEM of 3 differe
#Signiﬁcantly different from NGF alone, xSigniﬁcantly different from CBD alone, p b 0.05.3.9. CBD did not induce cellular differentiation in SH-SY5Y neuronal model
Retinoic acid (RA, 10 μM) induced cell differentiation (35.10± 3.72)
as compared to control (5.36 ± 1.51). CBD (1 μM) did not induce cellere incubatedwith NGF 100 ng/ml or CBD 1 μM in the presence/absence of 100 nMK252a
euritewith a length equal to or greater than the cell bodywere counted and expressed as a
nt experiments performed in triplicate (n = 9). *Signiﬁcantly different from controls;
Fig. 6. Effect of CBD on the differentiation of PC12 cells treatedwithMPP+. (A) Bar graph; (B) and (C) photomicrographs ofMPP+ group andMPP++CBD group, respectively. Cellswith at
least one neurite with a length equal to or greater than the cell bodywere counted and expressed as a percentage of the total cells in the ﬁeld. The results expressed are mean± SEM of 3
different experiments performed in triplicates (n = 9). NGF 100 ng/ml; MPP + 100 μM and CBD 1 μM. *Signiﬁcantly different from control; **Signiﬁcantly different from NGF; #Signiﬁ-
cantly different from MPP+; p b 0.05.
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duced (23.60 ± 3.30) the differentiation induced by RA alone (35.10 ±
3.72) as presented in Fig. 9. Phase-contrast photomicrographs of RA-
induced cells and RA plus CBD treated cells are presented in Fig. 9B
and C, respectively.
3.10. CBD increased the expression of synaptophysin, synapsin I and
GAP-43 in MPP+-treated PC12 cells
CBD signiﬁcantly increased the expression of synaptophysin (3.04±
0.12); GAP-43 (3.94 ± 0.12) and synapsin I (4.59 ± 0.59) as compared
to MPP+ alone (1.54 ± 0.16; 1.40 ± 0.44 and 2.55 ± 0.39, respectively
(Fig. 10A–D).
4. Discussion
The neurodegenerative diseases share commonmechanisms of tox-
icity, namely: neuroinﬂammation, excitotoxicity, mitochondrial dys-
function and reduced trophic support (Fagan and Campbell, 2014).
The neuroprotection of CBD has been observed in different models of
neurodegenerative diseases such as Parkinson's, Huntington's andAlzheimer's diseases, and it has been mainly associated with antioxi-
dant and anti-inﬂammatory mechanisms; however, these properties
alone cannot explain all the biological effects found in preclinical and
clinical investigations with CBD (Zuardi, 2008; Iuvone et al., 2009).
The present study evaluated the neurotrophic potential of CBD as a
mechanism of neuroprotection as well as the involvement of the NGF-
pathway. For this purpose, cell viability, neuritogenesis, expression of
NGF and neuronal proteins, and the involvement of NGF receptors
(trkA)were investigated in three cellular systems: (i) PC12 cells treated
with MPP+; (ii) NGF-stimulated PC12 cells and (iii) retinoic acid (RA)-
stimulated SH-SY5Y cells. PC12 cells were used as a model system for
neuronal differentiation because they expressmembrane-bound recep-
tors and cytosolic macromolecules similar to those expressed in neu-
rons. Besides that, PC12 are electrically excitable cells and secrete
neurotransmitters such as dopamine, norepinephrine and acetylcholine
(Shafer and Atchison, 1991; Satpute et al., 2010). The neurotoxin MPP+
is the active metabolite of the neurotoxin MPTP (1-methyl-4-phenyl-
1,2,5,6 tetrahydropyridine), which induces PD symptoms in exposed
humans. The mechanism of toxicity involves the uptake of MPP+ by
the dopaminergic neurons of the brain, inhibition of complex 1 of the
mitochondrial electron transport chain, mitochondrial dysfunction and
Fig. 7. Effect of CBD on the neuritogenesis of PC12 cells treated with NGF. No signiﬁcant
difference was observed between the effects of CBD alone and CBD + NGF. Data were
expressed as mean ± SEM of three experiments performed in triplicate. *Signiﬁcant as
compared to control (p b 0.05).
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pletes the dopamine content and induces cell death (Xu et al., 2005).
Therefore, MPP+ is a relevant neurotoxin to Parkinson's disease.
In order to establish the neurotoxicity model and calculate the IC50,
a dose–response curve (cell viability assay) of the neurotoxinMPP+was
performed in PC12 cells. The IC50 ofMPP+ (1mM)was used to evaluate
the neuroprotection of CBD against the cell death induced byMPP+.We
also investigated the possible neurotoxic effect of CBD on PC12 cells by
treating themwith a high concentration (10 μM) of CBD alone. This con-
centration of CBD (10 μM) did not alter the viability of PC12 cells as
compared to control. Then, cells were treated with 1 mM MPP+
(IC50) and CBD (1-10 μM) to investigate the protection against MPP+-
induced cell death. All concentrations of CBD increased cell viability of
MPP+-treated PC12 cells; however, the lowest concentration of CBDFig. 8. Effect of CBD on the levels of NGF of PC12 cells. No signiﬁcant difference was ob-
served between the effects of CBD and control. Data were expressed as mean ± SEM of
three experiments performed in triplicate. *Signiﬁcantly different from control; #Signiﬁ-
cantly different from MPP+; p b 0.05.(1 μM) was the most effective. Accordingly, a previous study showed
the protection of CBD against MPP+ in primary dopaminergic cell cul-
ture (Moldzio et al., 2012). The neuroprotective effect of CBD against an-
other dopaminergic neurotoxin, 6-OHDA, was shown in primary mixed
glial cultures from C57BL/6 mice and in male Sprague–Dawley rats
(Lastres-Becker et al., 2005). The cannabinoid receptors CB1 and CB2
seem to play an important role in neuroprotection; however, CBD has
very low afﬁnity for these receptors. The activation of CB2 is associated
with decrease of microglial activation, and the activation of CB1 recep-
tors is associatedwith the neuroprotection of the psychotropic cannabi-
noid delta-9-tetrahydrocannabinol (Δ9THC) (Ashton and Glass, 2007;
Carroll et al., 2012). The mechanism of neuroprotection of CBD remains
unknown (Chagas et al., 2014; Szaﬂarski and Bebin, 2014) and it might
occur via different pathways; mechanisms like normalization of gluta-
mate homeostasis (Fernandez-Ruiz et al., 2013) and reduction of
microglial activation (Martin-Moreno et al., 2011) have been proposed.
The present study suggests the involvement of neuritogenesis in the
neuroprotective mechanism of CBD. We observed that CBD alone in-
duced neuritogenesis on PC12 cells cultivated in reduced-serum medi-
um not supplemented with NGF and therefore, almost deprived of
growth factors. It is known that deprivation of growth factors leads to
apoptosis (Mesner et al., 1995). The treatment with CBDmight have re-
stored the trophic signaling, therefore decreasing apoptosis (as demon-
strated by caspase-3 activity), and therefore, increasing the viability of
PC12 cells. Besides inducing the neuritogenesis of PC12 cells, CBD also
protected against the inhibition of neuritogenesis induced by the neuro-
toxin MPP+, which suggests the contribution of neuritogenesis in the
mechanism of neuroprotection of CBD. It is known that, PC12 cells ex-
press trkA receptors, the main target of NGF. In the presence of NGF,
PC12 cells cease proliferation, differentiate, form neurites and increase
excitability, like neurons (Slotkin and Seidler, 2010), therefore, PC12
cells constitute a useful system for studying trkA function (Tsoulfas
et al., 1996). In the present study, we evaluated trkA function by using
K252a, a selective inhibitor of trk neurotrophin receptors (Morotti
et al., 2002) and we observed that it reduced the neuritogenesis
induced byCBDalone and byNGF alone. The effect of NGF,was inhibited
after 72 h-incubation, whereas the inhibition of CBD by K252awas only
signiﬁcant after 120 h-incubation. This difference might be related to
different interactions with the trkA receptor. Different ligands might
have distinct afﬁnities or even induce phosphorylation at different
sites of trk receptors (Huang and Reichardt, 2003; Longo and Massa,
2013).We also observed that the neuritogenic effect of CBD is not addi-
tive to the effect of NGF nor dependent on the presence of NGF. More-
over, CBD did not increase the levels of NGF. However, CBD attenuated
the decreased level of NGF induced byMPP+. Since CBD seems not to in-
crease the expression of NGF, the higher levels of NGF observed in
MPP+ + CBD as compared to MPP+ alone might be due to an indirect
mechanism. Altogether, these ﬁndings strongly suggest that CBD in-
duces neuritogenesis by activation of trkA receptors by amechanism in-
dependent of NGF. In neurons, the main pathway regulating apoptosis
seems to be mediated by growth factors and trk receptors. By this path-
way, the anti-apoptotic protein Bcl2 inhibits the mitochondrial release
of cytochrome c and the subsequent activation of the caspase cascade
that culminates with the activation of caspase-3, the ﬁnal executor of
apoptosis (Wolozin and Behl, 2000). Therefore, the activation of trkA re-
ceptors by CBD might have contributed to the decreased activity of
caspase-3 induced by CBD in cells treated with the neurotoxin MPP+.
CBD did not induce neuritogenesis on SH-SY5Y neuroblastoma cells,
which do not express trkA receptors (Encinas et al., 1999; Edsjo et al.,
2001). In linewith ourﬁndings, a study showed that CBDdid not protect
differentiated (retinoic acid-treated) SH-SY5Y neuroblastoma cells
against MPP+ toxicity (Carroll et al., 2012). Another study reported
that CBD did not increase neurite density or the viability of retinoic
acid-treated SH-SY5Yneuroblastoma cells exposed to 6-OHDA, a neuro-
toxin also relevant for Parkinson's disease (Schonhofen et al., 2015). The
distinct phenotypes of PC12 and SH-SY5Y neuroblastoma cells might
Fig. 9. Effect of CBD on the differentiation of SH-SY5Y cells (A) Bar graph; (B) and (C) photomicrographs of SH-SY5Y cells treatedwith retinoic acid and retinoic acid plus CBD, respectively.
The results expressed are mean ± SEM of 3 different experiments performed in triplicate (n = 9). RA, retinoic acid 10 μM and CBD 1 μM. *Signiﬁcantly different from control, p b 0.05.
#Signiﬁcantly different from RA, p b 0.05.
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toma derived cells have no or low expression of neurotrophin receptor
genes and treatment with retinoic acid induces the expression of func-
tional trkB and trkC, but not trkA (Encinas et al., 1999; Edsjo et al.,
2001). Additionally, a study reported that if SH-SY5Y cells are
transfectedwith trkA, they respond to NGF by increasing the expression
of the neuronal protein synaptophysin (Edsjo et al., 2001). Accordingly,
in our assays, CBD did not induce differentiation on SH-SY5Y cells, and,
surprisingly, reduced the neuritogenesis induced by retinoic acid. Addi-
tionally, a clinical study suggested that the beneﬁcial effects of CBD in
PD patients were not associated with alterations in the plasma levels
of BDNF, a ligand of trkB receptors (Encinas et al., 1999; Chagas et al.,
2014). Moreover, studies in animal models have shown that CBD does
not increase ormight even decrease the expression of BDNF and trkB re-
ceptors in the brain of mice and rats, suggesting that the neuroprotec-
tive effect of CBD is not mediated by trkB receptors (Magen et al.,
2009; Zanelati et al., 2010; ElBatsh et al., 2012), which supports our
ﬁndings. Altogether, these data suggest that CBD activates trkA recep-
tors, but does not activate trkB or trkC receptors. This is the ﬁrst study
to show the involvement of trkA receptors in the mechanism of neuro-
protection of CBD. To further explore this mechanism, we evaluated the
effect of CBD on the expression of neuronal proteins related to synapto-
genesis (synaptophysin and synapsin I) and axonal growth (GAP-43)
that are knowingly induced by NGF (Das et al., 2004). GAP-43 is the
most abundant neuron-speciﬁc protein in the growth cones, and it isused as a marker of neuronal differentiation (Encinas et al., 1999).
Synaptophysin is an abundant integral membrane protein on synaptic
vesicles (Cheung et al., 2009), whereas synapsin I is associated with
the cytoplasmic side of synaptic vesicles. Synaptophysin and synapsin
I represent useful markers of the synaptic vesicle membrane of nerve
terminals (Valtorta et al., 1989). CBD signiﬁcantly increased the expres-
sion of synaptophysin, GAP-43 and synapsin I as compared to MPP+
alone. These data suggest that CBD induces neurite formation and elon-
gation via up-regulation of GAP-43 and induces the formation of
synaptic vesicles via up-regulation of synaptophysin and synapsin I.
This is the ﬁrst study to show that CBD protects against the down-
regulation of these neuronal proteins induced by MPP+. The induction
of neuritogenesis and the restoration of the neuronal network have
been suggested as possible strategies for the treatment of neurodegen-
erative diseases (Sofroniew et al., 2001; Lad et al., 2003; Gottlieb et al.,
2010). However, the use of neurotrophic factors such as glial-derived
neurotrophic factor (GDNF), BDNF and NGF in neurorestorative thera-
pies is limited by the blood brain barrier (BBB), poor plasma stability
and pleiotropic effects mediated by the interactionwithmultiple recep-
tors (Allen et al., 2013; Longo and Massa, 2013). The identiﬁcation of
agents able to cross the BBB and to modulate speciﬁc systems of
neurotrophin/receptors would contribute to the treatment of neurolog-
ical disorders. The activation of trkA, for example, has been suggested as
a therapeutic strategy for Alzheimer's disease (Longo andMassa, 2013).
CBD is able to cross the blood brain barrier (Deiana et al., 2012) and to
Fig. 10. Effect of CBD on the expression of neuronal proteins in PC12 cells treated with MPP+. (A) Western blot membranes and bar graphs of (B) synaptophysin, (C) GAP-43 and
(D) synapsin I. The results expressed aremean± SEM of 3 different experiments performed in triplicate (n=9). MPP+ 100 μMand CBD 1 μM. *Signiﬁcantly different fromMPP+, p b 0.05.
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namely, activation of trkA receptors and increased expression of neuro-
nal proteins related to axonal growth and synaptogenesis. These effects
might be beneﬁcial in neurodegenerative processes such as Parkinson's
disease and should be further investigated.
5. Conclusions
CBD protects against the cell death and neurite loss induced by the
neurotoxin MPP+ on PC12 cells. The neuroprotection is not dependent
or additive to NGF and might involve the activation of trkA receptors
and increased expression of axonal and synaptogenic proteins. CBD
seems not to activate trkB (main receptor of BDNF) or trkC (main recep-
tor of GDNF) in SH-SY5Y cells and diminishes the neuritogenesis in-
duced by retinoic acid on these cells. Therefore, SH-SY5Y cells might
not be a suitable model to study the neuroprotective effects of CBD.
The NGF-like effects of CBD contribute to its neuroprotective activity
against the toxicity induced by MPP+, a neurotoxin relevant to
Parkinson's disease.
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